Advanced glycation end products (AGEs) and their involvement in liver disease

Current Pharmaceutical Design

Volumn 14, Issue 10, 2008, Pages 969-972

  Hyogo, Hideyuki ^a   Yamagishi, Sho Ichi ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AGEs; Fibrosis; Inflammation; Liver disease; Oxidative stress; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CANDESARTAN; CIGLITAZONE; REACTIVE OXYGEN METABOLITE; TELMISARTAN; TROGLITAZONE;

ANTIOXIDANT ACTIVITY; CARBOHYDRATE ANALYSIS; CATABOLISM; CELL DAMAGE; CELL SURVIVAL; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FUNCTION TEST; LIVER ISCHEMIA; LIVER PROTECTION; LIVER TOXICITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SENSITIVITY AND SPECIFICITY; STELLATE CELL;

ANIMALS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIVER DISEASES; OXIDATIVE STRESS; RECEPTORS, IMMUNOLOGIC;

EID: 44449166649     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784139701     Document Type: Review

References (50)

1. Takeuchi M, Kikuchi S, Sasaki N, Suzuki T, Watai T, Iwaki M, et al. Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. Curr Alzheimer Res 2004; 1: 39-46.
2. Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res 2003; 23:129-34.
3. Takeuchi M, Yamagishi S. TAGE (toxic AGEs) hypothesis in various chronic diseases. Med Hypotheses 2004; 63: 449-52.
4. Takeuchi M, Yamagishi S. Alternative routes for the formation of glyceraldehydes-derived AGEs (TAGE) in vivo. Med Hypotheses 2004; 63: 453-5.
5. Araki N, Ueno N, Chakrabarti B, Morino Y, Horiuchi S. Immuno-chemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J Biol Chem 1992; 267: 10211-4.
6. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995; 46: 223-34.
7. Makino H, Shikata K, Hironaka K, Kushiro M, Yamasaki Y, Sugimoto H, et al. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int 1995; 48: 517-26.
8. Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, et al. Immunohistochemical localization of advanced glycosylation end products in atherosclerotic lesions of human aorta using a novel specific monoclonal antibody. Am J Pathol 1995; 147: 654-67.
9. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
10. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-99.
11. Smith MA, Taneda S, Richey PL, Miyata S, Yan S-D, Stern D, et al. Advance Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 1994; 91: 5710-4.
12. Vitek MP, Bhattacharya Y, Glendening JM, Stopa E, Vlassara H, Bucala R, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 1994; 91: 4766-70.
13. Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 2001; 989: 256-62.
14. Takeuchi M, Bucala R, Suzuki T, Ohkubo T, Yamazaki M, Koike T, et al. Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J Neuropathol Exp Neurol 2000; 59: 1094-105.
15. Takeuchi M, Kikuchi S, Sasaki N. Suzuki T, Watai T, Iwaki M, et al. Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. Curr Alzheimer Res 2004; 1: 39-46.
16. Hofmann SM, Dong HJ, Li Z, Cai W, Altomonte J, Thung SN, et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse.Diabetes 2002; 51: 2082-9.
17. Sullivan CM, Futers TS, Barrett JH, Hudson BI, Freeman MS, Grant PJ. RAGE polymorphisms and the heritability of insulin resistance: The Leeds family study. Diab Vasc Dis Res 2005; 2: 42-4.
18. Unoki H, Bujo H, Yamagishi S, Takeuchi M, Imaizumi T, Saito Y. Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Res Clin Pract 2007; 76: 236-44.
19. Kuniyasu H, Chihara Y, Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 2003; 104: 722-7.
20. Abe R, Shimizu T, Sugawara H, Watanabe H, Nakamura H, Choei H, et al. Regulation of human malignant melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol 2004; 122: 461-7.
21. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005; 64: 92-100.
22. Bartling B, Demling N, Silber RE, Simm A. Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for advanced glycation end-products. Am J Respir Cell Mol Biol 2006; 34: 83-91.
23. Riuzzi F, Sorci G, Donato R. RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. Am J Pathol 2007; 171: 947-61.
24. Lee SJ, Lee KW. Protective effect of (-)-epigallocatechin gallate against advanced glycation endproducts-induced injury in neuronal cells. Biol Pharm Bull 2007; 30: 1369-73.
25. Bakshi N, Kunju LP, Giordano T, Shah RB. Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: diagnostic Implications. Appl Immunohistochem Mol Morphol 2007; 15310-5.
26. Tesarová P, Kalousová M, Jáchymová M, Mestek O, Petruzelka L, Zima T. Receptor for advanced glycation end products (RAGE) - soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest 2007; 25: 720-5.
27. Hiwatashi K, Ueno S, Abeyama K, Kubo F, Sakoda M, Maruyama I, et al. A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC. Ann Surg Oncol 2008; 15(3): 923-33.
28. Ekong U, Zeng S, Dun H, Feirt N, Guo J, Ippagunta N, et al. Blockade of the receptor for advanced glycation end products attenuates acetaminophen-induced hepatotoxicity in mice. J Gastroenterol Hepatol 2006; 21: 682-8.
29. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, et al. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 2006; 49: 3094-9.
30. Fehrenbach H, Weiskirchen R, Kasper M, Gressner AM. Upregulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology 2001; 34: 943-52.
31. Iwamoto K, Kanno K, Hyogo H, Yamagishi S, Takeuchi M, Tazuma S, et al. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol 2007; (in press).
32. Takata K, Horiuchi S, Araki N, Shiga M, Saitoh M, Morino Y. Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. J Biol Chem 1988; 263: 14819-25.
33. Smedsrod B, Melkko J, Araki N, Sano H, Horiuchi S. Advanced glycation end products are eliminated by scavenger-receptor mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells. Biochem J 1997; 322: 567-73.
34. Sebeková K, Kupcová V, Schinzel R, Heidland A. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation. J Hepatol 2002; 36: 66-71.
35. Hyogo H, Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, Sato T, et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22: 1112-9.
36. Yagmur E, Tacke F, Weiss C, Lahme B, Manns MP, Kiefer P, et al. Elevation of N epsilon-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis. Clin Biochem 2006; 39: 39-45.
37. Sengoelge G, Födinger M, Skoupy S, Ferrara I, Zangerle C, Rogy M, et al. Endothelial cell adhesion molecule and PMNL response to inflammatory stimuli and AGE-modified fibronectin. Kidney Int 1998; 54: 1637-51.
38. Yamagishi S, Takeuchi M. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drugs Exp Clin Res 2004; 30: 169-75.
39. Yamagishi S, Matsui T, Nakamura K, Takeuchi M. Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation. Int J Tissue React 2005; 27: 189-95.
40. Zhong Y, Li SH, Liu SM, Szmitko PE, He XQ, Fedak PW, et al. C-Reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Hypertension 2006; 48: 504-11.
41. Yamagishi SI, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, et al. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res 2007; 40: 10-5.
42. Hansen B, Svistounov D, Olsen R, Nagai R, Horiuchi S, Smedsrød B. Advanced glycation end products impair the scavenger function of rat hepatic sinusoidal endothelial cells. Diabetologia 2002; 45: 1379-88
43. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, et al. Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. FEBS Lett 2006; 580: 2788-96.
44. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Emaizumi T, Takeuchi M, et al. Pigment epithelium-derived factor ameliorates AGE-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation. Hormone Metab Res 2007; (in press).
45. Yoshida T, Yamagishi S, Matsui T, Nakamura K, Takeuchi M, Ueno T, et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-γ activation. J Int Med Res 2007; (in press).
46. Zeng S, Feirt N, Goldstein M, Guarrera J, Ippagunta N, Ekong U, et al. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 2004; 39: 422-32.
47. Cataldegirmen G, Zeng S, Feirt N, Ippagunta N, Dun H, Qu W, et al. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med 2005; 201: 473-84.
48. Beaugrand M, Seror O. Transcutaneous treatments of hepatocellular carcinoma in patients with cirrhosis: Present status and future developments. Curr Pharm Des 2007; 13(32): 3274-8.
49. Palasciano, G, Moschetta A, Palmieri VO, Grattagliano I, Iacobellis G, Portincasa P. Non-alcoholic fatty liver disease in the metabolic syndrome. Curr Pharm Des 2007; 13(21): 2193-8.
50. Yamagishi S, Ueda S, Okuda S. Flood-derived advanced glycation end products (AGEs): A novel therapeutic target for various disorders. Curr Pharm Des 2007; 13(27): 2832-6.